Table 7.
Summary of observations based on haemodynamic effects of oxytocin administered at first injection T1-T2 (Table 4) and second injection T2-T3 (Tables 5 and 6). For further explanation of comparisons, see Fig. 1, and for explanation of interpretations, see text
| Variable | Table 4 T1-T2 in OP group N = 24 |
Table 5 T2-T3 in PO group N = 26 |
Table 6 T1-T2 vs. T2-T3 in PO group N = 26 |
Summary of observations |
|---|---|---|---|---|
| MAP (mmHg) | No changea | Decrease | Decrease | Decrease |
| HR (bpm) | Increase | Increase | Increase | Increase |
| ECG ST index | No change | Decrease | Decrease | Decrease |
| PH | No changeb | Increase ➔ peripheral vasodilation | Increase ➔peripheral vasodilation | Increase ➔ peripheral vasodilation |
| ETc (ms) | Increase ➔ large-artery vasodilation, decreased afterload, decreased SVR, increased preload | No change | No change | Increase ➔ large-artery vasodilation, decreased afterload, decreased SVR, increased preload |
| EEI | No change | No change | N/Ac | No change |
| EEI@75 | No change | No change | N/Ac | No change |
| DI | Decrease ➔ small-artery vasodilation | Decrease ➔ small-artery vasodilation | Decrease ➔ small-artery vasodilation | Decrease ➔ small artery vasodilation |
| DI@75 | Decrease ➔ small-artery vasodilation | Decrease ➔ small-artery vasodilation | No change | Decrease ➔ small artery vasodilation |
| b/a | No change | No change | No change/decrease ➔ large-artery vasodilation, increase in LV ejection |
No change |
| d/a | No change | No change | No change | No change |
| AI | No change | No change | No change | No change |
a) MAP increased after both oxytocin and placebo
b) PH increased after both oxytocin and placebo, indicating peripheral vasodilation
c) EEI and EEI@75 statistics could not be performed due to too few cases in comparisons (N = 10)